Advertisement
Entire Site
Articles/Fact Sheets
Ask the Experts
Conference Coverage
E-Mail
Printable Single-Page
Glossary
Share
Index of Articles From 1997 Taglines
About TAGlines
December, 1997
The Worldwide Epidemic: Global AIDS Picture Worsens
Global Infectious Causes of Death (Table)
The Future of AIDS (Table)
The Twilight of Eradication: Infectious HIV Persists After Up to 2 1/2 Years of Triple Drug Therapy
November, 1997
The FDA Decides the Fate of Two Drugs for AIDS-Related Malignancies
Three New Antivirals Trickle From the Pipeline
Hamburg Highlights
Advertisement
October, 1997
Republicans and Pharmaceutical Industry Target the FDA
Low Key Dual Combo Appears First to Achieve the Unimaginable
September, 1997
Would-Be Eradicatee Looks Forward to Still Uncertain Future
Data from the 23rd ACTG Meeting Document Reduction in Number of Opportunistic Infections in the Era of HAART
The Opportunistic Infections of ACTG 320
(Table)
August, 1997
Roche Racks Up Millions In Early Saquinavir Sales While Unwitting Patients Prime Themselves for Protease X-Resistance
Metabolic Disturbances in HIV Infection Find Friend Not Foe in Protease Inhibitor Regimens
How the Triple Combos Stack Up
(Table)
June/July, 1997
Panel Embraces Maximum Viral Suppression as Goal of Therapy; Drug Company Bonanza Creates Headaches for Third Party Payers and AIDS Treatment Educators
May, 1997
Pediatric Therapy Lags Behind Adults'; Advocates Struggle to Maintain Funding
Opportunistic Infections in the Era of HAART: A Report from the 4th Conference on Retroviruses
April, 1997
Nelfinavir Becomes Fourth Protease Inhibitor to Hit Pharmacy Shelves
Government Study Finds Protease Based Triple Combination Keeps Patients Alive Longer Than Double Nuke
Sweating the Switch Between Protease Inhibitors
March, 1997
START Stopped: Strategic Conflicts and Issues of Long -Term Patient Management
Opportunistic Infections Continue to Vex the Lives of PWAs as Long As Immunodeficiency Remains
Treating OIs: How We're Doing
February, 1997
Druthers, Grim: Frightening Tales of Multiply Resistant HIV from D.C. Principles Panel
Backstepped: Dutch Research Team Challenges Ho/Shaw Pathogenetic HIV Model
Staring into the Precipice: resistance and cross-resistance among protease inhibitors
January, 1997
Delavirdine Disappoints at FDA
HIV in Lymphoid Tissue, and More from November's NIH AIDS Panel
Recent Research in Brief
Back to the Treatment Action Group index page
E-Mail
Printable Single-Page
Glossary
Share
My Health Tracker
Follow Us on Twitter
Widgets and RSS Feeds
U.S. ASO Finder
The First Man to Be Cured of AIDS: An Update on the Amazing Story -- This Month in HIV
OIs and Co-Infections and STIs -- Oh, My!
HIV Antiretrovirals in Development: An Update From ICAAC 2009
World AIDS Day 2009: Home
Back From the Brink: A Blog Entry by Thomas DeLorenzo
More >>
The First Man to Be Cured of AIDS: An Update on the Amazing Story -- This Month in HIV
A Few Coffees a Day Keep Liver Disease at Bay: Study
Obama Announces Ryan White CARE Act Reauthorization, Elimination of HIV Travel Ban
The Latest on H1N1 (Swine Flu) and HIV/AIDS
AIDS Criminals and Innocent Victims: Is There Anything Wrong With This Picture? A Blog Entry by Catherine Hanssens, Esq.
More >>
Advertisement
E-Mail
Printable Single-Page
Glossary
Share
